Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6H46

Human KRAS in complex with darpin K13

Summary for 6H46
Entry DOI10.2210/pdb6h46/pdb
DescriptorGTPase KRas, darpin K13, GUANOSINE-5'-DIPHOSPHATE, ... (5 entities in total)
Functional Keywordsgtp-ase, darpin, kras signalling, signaling protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight36676.03
Authors
Primary citationBery, N.,Legg, S.,Debreczeni, J.,Breed, J.,Embrey, K.,Stubbs, C.,Kolasinska-Zwierz, P.,Barrett, N.,Marwood, R.,Watson, J.,Tart, J.,Overman, R.,Miller, A.,Phillips, C.,Minter, R.,Rabbitts, T.H.
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.
Nat Commun, 10:2607-2607, 2019
Cited by
PubMed Abstract: Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that specifically inhibit the KRAS isoform by binding to an allosteric site encompassing the region around KRAS-specific residue histidine 95 at the helix α3/loop 7/helix α4 interface. We show that these DARPins specifically inhibit KRAS/effector interactions and the dependent downstream signalling pathways in cancer cells. Binding by the DARPins at that region influences KRAS/effector interactions in different ways, including KRAS nucleotide exchange and inhibiting KRAS dimerization at the plasma membrane. These results highlight the importance of targeting the α3/loop 7/α4 interface, a previously untargeted site in RAS, for specifically inhibiting KRAS function.
PubMed: 31197133
DOI: 10.1038/s41467-019-10419-2
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.22 Å)
Structure validation

235458

PDB entries from 2025-04-30

PDB statisticsPDBj update infoContact PDBjnumon